Revvity (NYSE:RVTY) Sets New 12-Month High – Time to Buy?

Shares of Revvity Inc. (NYSE:RVTY) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $131.09 and last traded at $129.91, with a volume of 100609 shares changing hands. The stock had previously closed at $126.59.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. TD Cowen restated a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Wolfe Research initiated coverage on shares of Revvity in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Royal Bank Of Canada began coverage on shares of Revvity in a research report on Tuesday. They set a “sector perform” rating and a $135.00 price target on the stock. Evercore reissued an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Finally, Robert W. Baird set a $117.00 target price on shares of Revvity in a report on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, Revvity currently has a consensus rating of “Hold” and an average target price of $110.58.

Revvity Trading Up 2.4%

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The company has a market cap of $14.47 billion, a P/E ratio of 61.74, a P/E/G ratio of 2.34 and a beta of 1.09. The business has a fifty day simple moving average of $115.22 and a 200 day simple moving average of $101.55.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. During the same period in the prior year, the company earned $1.18 earnings per share. The firm’s revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity’s dividend payout ratio (DPR) is currently 13.33%.

Institutional Trading of Revvity

A number of large investors have recently modified their holdings of the company. California State Teachers Retirement System lifted its holdings in Revvity by 19.8% in the first quarter. California State Teachers Retirement System now owns 133,809 shares of the company’s stock worth $11,723,000 after purchasing an additional 22,075 shares during the period. Bank of New York Mellon Corp bought a new position in Revvity during the second quarter valued at approximately $78,766,000. Corient Private Wealth LLC raised its position in Revvity by 985.0% during the fourth quarter. Corient Private Wealth LLC now owns 126,568 shares of the company’s stock valued at $12,245,000 after acquiring an additional 114,903 shares in the last quarter. Diamond Hill Capital Management Inc. lifted its stake in Revvity by 6.3% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 426,899 shares of the company’s stock valued at $41,302,000 after acquiring an additional 25,233 shares during the last quarter. Finally, Tocqueville Asset Management L.P. bought a new stake in Revvity in the second quarter worth approximately $4,791,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.